Albayrak, YakupBeyazyüz, MuratAbbak, ÖzlemAltındağ, Ece2022-05-112022-05-1120191738-10882093-4327https://doi.org/10.9758/cpn.2019.17.1.134https://hdl.handle.net/20.500.11776/9068Rabbit Syndrome is an uncommon side effect of antipsychotic treatment. Although it is usually associated with typical antipsychotics, it can also be related to atypical antipsychotics. Anticholinergics are the most accepted treatment approach in treating Rabbit Syndrome. Fluvoxamine is a member of selective serotonin reuptake inhibitors and it is a potent agonist of sigma 1 receptors. In this article, we report a Rabbit Syndrome case who has benefited from fluvoxamine, in terms of both depressive disorder and Rabbit Syndrome; and present the data on the effects of sigma 1 agonist fluvoxamine on numerous movement disorders.en10.9758/cpn.2019.17.1.134info:eu-repo/semantics/openAccessRabbit syndromeSigma receptorsSide effectFluvoxamineSerotonin Reuptake InhibitorsClinical-ImplicationsTardive-DyskinesiaReceptor AgonistsChaperoneLigandsCortexBrainScaleEditorial171134138Q3WOS:0004559248000162-s2.0-8506080097030690950Q2